Monthly SOM230C for Recurrent or Progressive Meningioma

Inclusion Criteria:

* 18 years of age or older
* Radiographically measurable disease on contrast-enhanced MRI or CT images
* Karnofsky Performance status of 60 or greater
* Life expectancy of at least 3 months
* Histologically confirmed diagnosis of recurrent or progressive intracranial meningioma(s). This includes benign, atypical, or malignant meningioma; patients with neurofibromatosis type 1 or 2 may participate. Participants without histological confirmation but a classic radiographic picture of meningioma may also enroll. Patients with neurofibromatosis type 2 and a classic radiographic picture of meningioma may also enroll without histological confirmation
* At least ten unstained standard (4-5 micron) paraffin slides for immunohistochemistry. Participants who have not had a surgical procedure are exempt from this requirement
* Unequivocal evidence for tumor progression by MRI (or CT scan if MRI is contraindicated)
* MRI or CT must be performed within 14 days of registration
* Patients with malignant meningiomas who require corticosteroids must be on a stable dose for at least 5 days prior to baseline imaging.
* For patients who have been treated with external beam radiation, interstitial brachytherapy, or radiosurgery, an interval of 4 or more weeks must have elapses from the completion of radiation therapy to study drug administration, and there must be evidence of tumor progression.
* There is no limit on the number of prior therapies

Exclusion Criteria:

* Any cytotoxic chemotherapy, radiation, immunotherapy, or experimental therapy within 4 weeks prior to study drug administration
* Prior therapy with somatostatin, andy somatostatin analogue, or any other hormonal treatment prescribed for the purpose of treating meningioma
* Major surgery within 4 weeks prior to study drug administration
* Malabsorption syndrome, short bowel or chologenic diarrhea not controlled by specific therapeutic means
* Poorly controlled diabetes mellitus
* Symptomatic cholelithiasis
* Congestive heart failure, unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia, advanced heart block or a history of acute myocardial infarction within the six months preceding enrollment
* QTc \> 450 msec
* Risk factors for Torsades de Pointes such as hypokalemia (\< 3.5 mmol/L) not corrected by treatment, hypomagnesemia (\< 0.7 mmol/L or \< 1.6 mg/dL) not corrected by treatment, cardiac failure, clinically significant/symptomatic bradycardia, or high-grade AV block
* Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure
* Concomitant medication(s) known to increase the QT interval within 4 weeks prior to study drug administration
* Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis with serum bilirubin \> 2x ULN, serum albumin \< 0.67 LLN, or ALT or AST more than 2 x ULN
* Any other primary malignancy within the past 3 years (with the exception of basal cell carcinoma or carcinoma in situ of the cervix)
* Active or suspected acute or chronic, uncontrolled infection or any history of immunocompromise, including any positive HIV test result
* Abnormal coagulation studies (PT or PTT elevated by 30% above normal limits)
* Use of anticoagulant medications (not including anti-platelet medications)
* Lab values as specified in the protocol
* Any current or prior medical condition that may interfere with the conduct of the study or the evaluation of its results in the opinion of the investigator
* Pregnancy or lactation, or failure to practice a medically acceptable method of birth control
* History of alcohol or drug abuse in the 6 month period before study enrollment
* Participation in any clinical investigation with an investigational drug within 1 month prior to study drug administration
* Known hypersensitivity to somatostatin analogues or any component of the pasireotide or octreotide LAR os s.c. formulations